Nasdaq GlobeNewswire

Altus Group Launches Next Generation Software Platform ARGUS Cloud and Web Application ARGUS Acquire to Enhance Investment Performance for Commercial Real Estate Industry

Del

ARGUS Cloud to power new web-based applications, increase user collaboration and improve ability to leverage CRE data

TORONTO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group”) (TSX: AIF), a leading provider of software, data solutions and independent advisory services to the global commercial real estate (“CRE”) industry, announced today the launch of ARGUS Cloud and ARGUS Acquire. ARGUS Cloud is a cloud-based platform for CRE asset and investment management that leverages functionality and data from industry-leading ARGUS solutions to enhance decision-making and portfolio transparency. ARGUS Acquire is the first of several integrated web-based applications to be powered on the ARGUS Cloud platform.

ARGUS Cloud enables greater collaboration and streamlines workflows across teams and business functions by storing all information in one centralized location. It seamlessly integrates with industry-standard ARGUS Enterprise (“AE”), delivering greater value to users through the ability to store, backup and access ARGUS files and leverage additional Altus Group cloud solutions. The ARGUS Cloud platform will leverage the intelligence of AE to both support existing on-premise solutions and power a series of new critical web-based applications designed to better manage the challenges facing today’s CRE professionals.

ARGUS Acquire, the first in a series of new web-based applications, is a deal management solution that has been tailor-made to enable acquisitions teams to efficiently construct sound financial models, pitch winning deal strategies and meet capital deployment targets. It provides complete top-down visibility of acquisition deals and pipelines, creating greater efficiency and consistency.

“With the launch of ARGUS Cloud, we’re creating a connected ecosystem for the commercial real estate industry by delivering innovative cloud-based solutions that provide complete portfolio transparency and insights,” said Bob Courteau, Chief Executive Officer at Altus Group. “This is a key part of our product and partner strategy, and the next step in our plan to build additional integrated end-to-end solutions that will streamline business processes, leverage third-party data sources and reduce complexity within the CRE industry.”

ARGUS Cloud provides a number of key capabilities:

  • Store and back up files in the cloud – seamlessly move your organization’s models into a centralized cloud database for storage and accessibility with on-premise and web-based ARGUS applications. Users can easily audit files and maintain a secure record of changes made to any asset.
     
  • Access and collaborate on your files any time – access your models any time through a single-point of entry to ARGUS on-premise and web-based applications, regardless of location. Centrally located models allow users to collaborate more easily across their business and with partners which simplifies processes and ensures a consistent view of assets throughout their lifecycle.
     
  • Connect to the next generation of applications – use stored data and an industry-standard AE calculation engine to power the next generation of ARGUS applications, beginning with ARGUS Acquire. Cloud infrastructure allows streamlined workflows between on-premise and web-based applications and will enable users to connect to their growing CRE technology ecosystem.

For more information on ARGUS Cloud, please visit https://argus.altusgroup.com/argus-cloud/. For more information on ARGUS Acquire, please visit https://argus.altusgroup.com/argus-acquire/.

About Altus Group Limited

Altus Group Limited is a leading provider of software, data solutions and independent advisory services to the global commercial real estate industry. Our businesses, Altus Analytics and Altus Expert Services, reflect decades of experience, a range of expertise, and technology-enabled capabilities. Our solutions empower clients to analyze, gain insight and recognize value on their real estate investments. Headquartered in Canada, we have approximately 2,500 employees around the world, with operations in North America, Europe and Asia Pacific. Our clients include some of the world’s largest real estate industry participants. Altus Group pays a quarterly dividend of $0.15 per share and our shares are traded on the TSX under the symbol AIF.

For more information on Altus Group, please visit: www.altusgroup.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Altus Group Limited

Jeff Hayward
Vice President, Global Marketing & Communications
416-234-4212
jeff.hayward@altusgroup.com

Camilla Bartosiewicz
Vice President, Investor Relations
416-641-9773
camilla.bartosiewicz@altusgroup.com

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

ERYTECH Partners with New York Blood Center for Red Blood Cell Supply and Research15.11.2018 22:05Pressemelding

LYON, France and CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a strategic partnership with New York Blood Center (NYBC) for red blood cell supply and research. The partnership encompasses NYBC becoming a long-term supplier of donor red blood cells (RBC) to ERYTECH, enabling ERYTECH to diversify and broaden its supply of RBC source materials for the production of eryaspase and future product candidates derived from its proprietary ERYCAPS® platform as the company ramps up clinical development. Specifically for the Phase 3 trial in second-line metastatic pancreatic cancer that recently started enrolling patients in Europe, and the Phase 2 trial in first-line triple negative breast cancer (TNBC), which are both expected to begin enrollment in the United States early in 2019. The partnershi

Zageno Deepens Engagement with Scientists and Vendors through Its Meaningful and Unbiased Rating System for Scientific Products — Scientific Score gets Algorithm Update15.11.2018 15:37Pressemelding

Call for Contributions: Zageno’s rating system for scientific products — the Scientific Score — adds a crucial dimension to help research scientists purchase the right material for their experiment. Scientists: share your experimental data and professional experience about products; Life Science Vendors: provide additional product-specific resources and data points to make your products reach the right scientist CAMBRIDGE, Mass. USA and BERLIN, Germany, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Zageno Inc., the largest and fastest-growing online marketplace for research materials, today issues an open call for scientists and vendors alike to contribute to the continuous improvement of the Scientific Score. Designed as an unbiased indicator to help purchasing scientists navigate the enormous amount of product information, the Scientific Score is the result of proprietary algorithms calculating and weighing different data points across multiple information formats. Among others, factors like rec

SignalFx Delivers Next Generation of Application Performance Monitoring15.11.2018 15:00Pressemelding

The first to enable directed troubleshooting for applications and microservices SAN MATEO, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- SignalFx, the leader in real-time cloud monitoring for infrastructure, microservices, and applications, today unveiled SignalFx Microservices APM™, the industry’s first real-time application performance monitoring solution designed to accelerate troubleshooting for DevOps teams through advanced real-time analytics. Powered by NoSample™ distributed tracing architecture, SignalFx Microservices APM observes every single transaction – not just a small random sample – and reports on every anomaly. With the new Outlier Analyzer™, the most challenging issues can now be pinpointed and resolved with a single click. SignalFx Microservices APM is built on top of SignalFx’s advanced streaming analytics platform for metrics which applies unsurpassed data science in real-time to identify the root cause of critical application problems. Integration with advanced automat

Motiv Ring Expands International Footprint and Delivers Industry-First Sizing Process15.11.2018 15:00Pressemelding

The wearable ring lands in 20 new countries and eight new stores, and introduces frictionless sizing method SAN FRANCISCO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Motiv Inc., creators of breakthrough wearable technology, today announced an increase of its product availability through new international availability and a new digital sizing set alternative. Motiv Ring’s international expansion will be through its website MyMotiv.com. Featured countries include: North America (Canada), Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, Latvia, Netherlands, Poland, Portugal, Spain, Sweden, United Kingdom, Norway and Switzerland), as well as Japan, Taiwan, Turkey, Australia and New Zealand. Good fit is imperative to great functionality. To date, Motiv Ring users select their sizes after receiving a physical sizing kit in the mail. Releasing in Open Beta , Motiv Ring users will now have the additional option of determining their Motiv size via a

Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 201815.11.2018 14:30Pressemelding

Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone and KOL discussion of trans-diagnostic approach to treating negative symptoms in CNS/psychiatry diseases WALTHAM, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a roluperidone update and key opinion leader event on Tuesday, November 20, 2018 beginning at 8:00 a.m. Eastern Time in New York. Members of Minerva’s senior management will be joined by an expert key opinion leader. Discussions will feature the following speakers and topics: Gregory P. Strauss, Ph.D., Assistant Professor; Director: Clinical Affective Neuroscience Laboratory; Director: Georgia Psychiatric Risk Evaluation Program; Depa

New Pancreatic Ductal Adenocarcinoma Research Published in Journal of Visualized Experiments15.11.2018 14:00Pressemelding

Paper describes well-established protocols for PDAC orthotopic tumor homograft model development and immunoprofiling SAN DIEGO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has recently published in the Journal of Visual Experiments the establishment and immunological characterization of PDAC orthotopic tumor homograft models. Pancreatic ductal adenocarcinoma (PDAC) research represents an area of high unmet medical need. PDAC fails to respond to a range of cancer therapies, including immunotherapy, partially due to an abundant tumor microenvironment (TME), that protects tumor cells from treatment. The development of new therapeutic and combination strategies requires highly relevant preclinical models recapitulating the complexity of PDAC tumors including the TME. Transplantable PDAC models, developed by pass

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom